Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30861566 | 1.00 | TAAR1 (0.43) | TAAR1SRD5A1PNMTASIC3HTR2A | |
| SCHEMBL7684984 | 0.88 | CHRNA7 (0.41) | TAAR1 | |
| SCHEMBL3866433 | 0.86 | CHRNA7 (0.46) | SRD5A1 | |
| SCHEMBL20053843 | 0.84 | TAAR1 (0.64) | TAAR1 | |
| SCHEMBL17552310 | 0.84 | TAAR1 (0.64) | TAAR1 | |
| SCHEMBL2571280 | 0.83 | SRD5A1 (0.48) | SRD5A1 | |
| SCHEMBL2572769 | 0.83 | SRD5A1 (0.48) | SRD5A1 | |
| SCHEMBL2571011 | 0.83 | SRD5A1 (0.48) | SRD5A1 | |
| SCHEMBL24570919 | 0.82 | SRD5A1 (0.44) | SRD5A1HTR2AHTR2CHTR2B | |
| SCHEMBL3092592 | 0.82 | FNTA (0.53) | TAAR1SRD5A1HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | DONG-A ST CO., LTD. (KR) | 2026-05-28 | — | — | US | disclosed |
| EP-4605395-A2 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | Dong-A ST Co., Ltd. (KR) | 2025-08-27 | — | — | EP | disclosed |
| WO-2024084448-A2 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | DONG-A ST CO., LTD. (KR) | 2024-04-25 | — | — | WO | disclosed |
| CN-116478145-B | ALK2 kinase inhibitors | 杭州邦顺制药有限公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2023198114-A1 | ALK2 KINASE INHIBITOR | 杭州邦顺制药有限公司 | 2023-10-19 | — | — | WO | disclosed |
| CN-116478145-A | ALK2 kinase inhibitors | 杭州邦顺制药有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-9586928-B2 | Modulators of the nuclear hormone receptor ROR | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586928-B2 | Modulators of the nuclear hormone receptor ROR | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586928-B2 | Modulators of the nuclear hormone receptor ROR | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-03-07 | — | — | US | disclosed |
| US-20140187554-A1 | MODULATORS OF THE NUCLEAR HORMONE RECEPTOR ROR | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-07-03 | — | — | US | disclosed |
| WO-2012158784-A2 | MODULATORS OF THE NUCLEAR HORMONE RECEPTOR ROR | KAMENECKA THEODORE MARK (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012158784-A2 | MODULATORS OF THE NUCLEAR HORMONE RECEPTOR ROR | KAMENECKA THEODORE MARK (US) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187554-A1 | MODULATORS OF THE NUCLEAR HORMONE RECEPTOR ROR | RORB, RORA, RORC | TAAR1 643/4885SRD5A1 295/4885PNMT 3803/4885 |
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | AXL, ERBB2, ERBB3 | TAAR1 475/4885SRD5A1 2020/4885PNMT 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.